Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 14:9:921955.
doi: 10.3389/fcvm.2022.921955. eCollection 2022.

Impact of P2Y12 inhibitors on cardiovascular outcomes of Korean acute myocardial infarction patients with baseline thrombocytopenia

Seok Oh  1 , Myung Ho Jeong  1   2 , Kyung Hoon Cho  1 , Min Chul Kim  1   2 , Doo Sun Sim  1   2 , Young Joon Hong  1   2 , Ju Han Kim  1   2 , Youngkeun Ahn  1   2
Affiliations

Impact of P2Y12 inhibitors on cardiovascular outcomes of Korean acute myocardial infarction patients with baseline thrombocytopenia

Seok Oh et al. Front Cardiovasc Med. .

Abstract

Background: Antiplatelet therapy is crucial for managing acute myocardial infarction (AMI) and reducing adverse ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stents. However, the ideal P2Y12 inhibitor for patients-particularly East Asians-with AMI and low platelet levels remains unknown. We evaluated the impact of various potencies of P2Y12 receptors on major cardiovascular outcomes of AMI patients with thrombocytopenia in Korea.

Methods: We analyzed the clinical and outcome data of 800 AMI patients with baseline platelet counts <150 × 103/μL who underwent PCI between November 2011 and June 2015. All patient data were obtained from the Korea Acute Myocardial Infarction Registry-National Institutes of Health registry. Subjects were allocated to group A (n = 244; treated with potent P2Y12 inhibitors) or group B (n = 556; treated with clopidogrel). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs).

Results: At the 3-year follow-up, clinical outcomes appeared better in group A than in Group B. However, after propensity score weighting-adjusted analysis, these findings were statistically attenuated, showing a similar incidence of MACCEs between the two groups.

Conclusions: Clopidogrel may be reasonable for patients with low platelet counts and is associated with comparable outcomes to potent P2Y12 inhibitors for Korean AMI patients.

Keywords: Republic of Korea; antiplatelet drugs; myocardial infarction; percutaneous coronary intervention; thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study scheme. Data of a total of 800 AMI patients from the KAMIR-NIH registry were analyzed. AMI, acute myocardial infarction; KAMIR-NIH, korea acute myocardial infarction registry-national institutes of health; PCI, percutaneous coronary intervention.
Figure 2
Figure 2
Event rates of clinical outcomes for all the patients after a 3-year follow-up (before PSM-and IPTW-adjusted analysis). The Kaplan–Meier curves for cumulative event rates according to the type of P2Y12 receptor inhibitors are shown. The red curve indicates group A, and the blue curve indicates group B. CVA, cerebrovascular accident; IPTW, inverse probability of treatment weighting; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction.
Figure 3
Figure 3
Event rates of clinical outcomes for all patients after a 3-year follow-up (after PSM-adjusted analysis). The Kaplan–Meier curves for cumulative event rates according to the type of P2Y12 receptor inhibitors are shown. The red curve indicates group A, and the blue curve indicates group B. CVA, cerebrovascular accident; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; PSM, propensity score matching.
Figure 4
Figure 4
Event rates of clinical outcomes for all patients after a 3-year follow-up (after IPTW-adjusted analysis). The Kaplan–Meier curves for cumulative event rates according to the type of P2Y12 receptor inhibitors are shown. The red curve indicates group A, and the blue curve indicates group B. CVA, cerebrovascular accident; IPTW, inverse probability of treatment weighting; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction.
See this image and copyright information in PMC

References

    1. Ibanez B, James S, Agewell S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (2018) 39:119–77. 10.1093/eurheart/ehx393 - DOI - PubMed
    1. Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. (2002) 23:550–7. 10.1053/euhj.2001.2901 - DOI - PubMed
    1. Kang J, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”. Korean Circ J. (2018) 48:537–51. 10.4070/kcj.2018.0166 - DOI - PMC - PubMed
    1. Liu R, Liu J, Yang J, Gao Z, Zhao X, Chen J et al. Association of thrombocytopenia with in-hospital outcome in patients with acute ST-segment elevated myocardial infarction. Platelets. (2019) 30:844–53. 10.1080/09537104.2018.1529298 - DOI - PubMed
    1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. (2019) 40:87–165. 10.1093/eurheartj/ehy855 - DOI - PubMed